Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Sanofi Synthelabo — Investor Day (September 2003)
98 slides from Sanofi Sa's investor day presentation, Sep 5, 2003
Slide 1: Information meeting
sertonier 20. Information meeting sanofi~synthelabo _ Because health matters
Slide 2: Forward-looking statements
[This document contains statements that constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or beliefs and are subject to a number of factors and uncertainties that coul
Slide 3: sanofi~synthelabo
sanofi~synthelabo Because health matt
Slide 4: An excellent First Half 2003 in terms of sales and profit growth
An excellent First Half 2003 in terms of sales and profit growth: sanofi~synthelabo Becanse Beale aters * before exceptional items and goodwill amorizaton
Slide 5: 1st half 2003: An acceleration in sales growth
15t half 2003: An acceleration in sales growth 15t half 2003 sales of 4 “blockbusters” in million euros | H1 2003 sales: Consolidated: + 14.4% | Consolidated sales Developed: + 15.0% = S12002 ™S12003 = Q1 2003 Sales Consolidated: +13,4% Développed: +98% = Q2 2003 sales Plavix amcsen APROVEL Eloxatin
Slide 6: Twice the market growth
8 companies (ims* data - YTD June 2003) Twice the market* growth Amgen Novartis anofi-Syrthelabo EISAL J&d |] Takeda Eli Lilly B. Ingelheim Abbott Piizer |. Aventis Roche Market Schering AG |. Bayer Merck Gsk wyeth BMS Astrazeneca Schering Plough Sales growth of the leading 20 pharmaceutical +362 %
Slide 7: 1st half 2003: +18.6% growth in EPS
15t half 2003: + 18.6% growth in EPS* | H1 2003 Operational profit growth: + 12.8% = Income from currency hedging included in financial income = Ifincluded in operating income, H1 2003 operating profit: + 15.9% | H1 2003 Net profit* growth: + 14.4% | H1 2003 EPS* growth : + 18.6% TLE in million euro
Slide 8: 1st half 2003: +31.9% growth in EPS at 2002 exchange rates
15t half 2003: + 31.9% growth in EPS* at 2002 exchange rates At 2002 exchange rates: [| H1 2003 Operational profit growth: + 30.3% [High level of investment maintained in R&D: + 12.9% = Life Cycle Management of strategics products = 9 products in phase Il [| H1 2003 Net profit" growth: + 27.5% | H1
Slide 9: A sustained and regular business operations growth
A sustained and regular business operations growth | Breakdown of Net Profit Growth factors 1999 / 2000 / 2001/ | H12002/ 2000 2001 2002 Hi 2003 Business Operations Currency fluctuations Synergies +10% - - Increase rights in Lorex JV +6% +7% +4% NET PROFIT GROWTH + 54% + 43% + 28% +14% sanofi~synthe
Slide 10: 1st half 2003: Continued wave of positive news
15t half 2003: Continued wave of positive news [ Eligard®: US Registration of the 4-month formulation (February 2003) | Arixtra®: Indication extension program on schedule | Eloxatin®: The new reference treatment in colorectal cancer | Uroxatral®: US registration June 2003 sanofi~synthelabo Becanse B
Slide 11: Operations
Operations sanofi~synthelabo Because health mat
Slide 12: Outperforming the worldwide market
Outperforming the worldwide market Strategic products performance . Elexatin Katia linss - 4, MSIGERS Wow: “A (10 channele)+ Europe (17 counties Retail) + Japan Retal & heepital) lead to accelerated growth rate worldwide Sanofi-Synthelabo vs market growth! 202% en 223% 200% 11.4% 157% ge 13.0% a 105
Slide 13: Continued double digit growth
Continued double digit growth 4% Half, 2003 Consolidated sales Developed sales ‘Europe 2,320 +7.9% 2,373 +8.5% USA 884 + 40.1% 1,718 + 25.6% Other countries 699 +11.0% 822 +14.6% Total 3,903 Developed Sales incude 100% of ales ftom agreements with BMS, Fujisawa and Organon, sanoFi~synthelabo (Change
Slide 14: USA: Accelerating growth
USA: Accelerating growth | 1% Half 2003 consolidated demand sales 2003 Demand growth’ in value ti = IMS YTD 06/03 grew at +36% in a market growing at only +10% Developed ap src | Strong growth in demand accompanied by lower invoicing has led to reduced inventory levels Consolidated 136% (23%) }0% (1
Slide 15: Europe: Growth superior to market
Europe: Growth superior to market | Pharma market environment changes : = France: — dereimbursement plan = Germany: 6% contribution to insurers on non referenced products = Italy 2% price reduction | The 6 Strategic products = Eloxatine® (+42%) = Plavix® — (#32%)8 Aprovel® (+26%) Xatral® (17%) Stiln
Slide 16: Other countries: Double digit growth
Other countries: Double digit growth’ | Asia | Australia / Japan = Business activity limited by SARS = Preparing stand alone activity in Japan = Strong growth specially in Korea, Taiwan and Australia | Latin America = Macro economic and currency conditions stil difficult = Restructuring initiated in
Slide 17: Most successful oncology launch in the USA
Most successful oncology Elexeatin launch in the USA Worldwide sales umulative US sales of oncology products? (EUR m, common zero from launch) 500 —ELoxarine@ — —sLeevece —TaxaLe CAMPTOSAR® —RITUKAN® GEMZAR® 0} —taxoreRe® 00 200 10 MOMS MB MD MI2 MAEM MT. H1 2002 H1 2003 "Other countries = USA Month
Slide 18: Eloxatin in colorectal cancer
colorectal cancer Market leader in Europe... European CRC sales! (EUR m, Top 5 countries) BEtoxatin® ™=Canpto 84588 8 8 5 8 8 o 5 4, IMSIGERS Hospital OTR 2. OTH, Maket: Camptosar + Eloxatin Becoming the new reference in Blexatin ...with a rapid US penetration Eloxatin® market share in USA (% of new
Slide 19: Adjuvant treatment in colorectal cancer
Adjuvant treatment in Elexeatin colorectal cancer [MOSAIC results: Disease free survival by treatment arm 3 years 1 —— FOLFOX4 (n=1123) 77.8% — LV5FU2 (n=1123) 72.9% ase free survival p<0.01 : 4 i ow 6 8 8 8 8 8 & 4 months 23% risk reduction in the FOLFOX4 arm sanofi~synthelabo Becanse Beale aters
Slide 20: First line treatment in advanced colorectal cancer
First line treatment in advanced Blexatin colorectal cancer {.N9741 results: Overall survival Odds Reduction: IFL vs. FOLFOX IFL vs. IROX 34% (p=0.0001) 20% (p=0.04) 19.5 Median survival (months) IFL FOLFOX IROX sanofi~synthelabo
Slide 21: Life Cycle Management Eloxatin
Life Cycle Management Elexeatin { Colorectal cancer = In adjuvant and neo-adjuvant settings (isolated liver metastases) = Efficacy of FOLFOX regimen with: ~ bevacizumab — (second line, first line, adjuvant) ~ cetuximab — (second line, first line) ~ vatalanib — (second line, first line) | Other cance
Slide 22: From Care to Cure in Colorectal Cancer
From Care to Cure Blexatin in Colorectal Cancer ‘2nd g 314 fine 4 line Adjuvant NCW NCCTG study MOSAIC study. ema Scena Survival benefit= 19.5months 28% RR of relapse vs. SFULV (#4.7 months vs. IFL) vs. SFULV 72,000 patients p 2 aay eUah} 100,000 patients Increase in 2006 sales objective: |? FUR 1.5
Slide 23: Xatral: A new global brand
A new global brand $;atrab ins. | The most dynamic of its class' and market leader in Xatra® consolidated sales France and Sweden = Sales in Italy have doubled in H1 2003 after launch of OD form | Unique positioning: treat BPH, respect sexual function | Question marks over future of 5-ARI present po
Slide 24: Uroxatral: A new global brand
A new global brand i USA BPH Market? | US market size : 1 EUR Bn, {EUR m) trend +14", favorable circumstances 1025 ® Alpha blockers | FDA approval 06/03, launch Q4 03 5 alphareductase inhibitors | Included into AUA 2003 guidelines | Agressive launch plan fully competitive oe | Taking advantage of pr
Slide 25: Life Cycle Management Arixtra
Life Cycle Management Arvitra | Long-term prevention of VTE* in hip fracture = US: registered in June 2003 = Europe: CPMP positive opinion in July 2003 | Curative treatment of VTE* = Europe & US: submitted in July 2003 | Ongoing development * Prevention of VTE* in high risk surgery (PEGASUS, APOLLO)
Slide 26: Efficacy in abdominal surgery Arixtra
Efficacy in abdominal surgery AriXtra I {A trend towards superior efficacy of fondaparinux over dalteparin Cancer surgery patients (all VTE) 2 Odds Reduction = 40.5% = 0.02 VTE reduction Odds Reduction = 25.8% dalteparin — fondaparinux (651712) e31e08) daltepari fondaparinux 2500 U pre-op and post-o
Slide 27: Efficacy in abdominal surgery Arixtra
— Efficacy in abdominal surgery AriXtra | Treatment-related deaths from first administration up to Day 32 = As treated patients dalteparin n= 1425 n (%) Death associated 15 (1.1%) Death not associated with VTE or bleeding 332.9%) | 40 (28%) Total 40(28%) | 559%) sanofi~synthelabo Becanse Beale aters
Slide 28: Efficacy in medical patients Arixtra
Efficacy in Medical* patients AriXtra I Death adjudication outcome storm | 7m | 20 | 10a ean | 80a) Odds Reduction = 49.5% p= 0.029 placebo fondaparinux 41323) 187321) + Acutalyill patients requiring atleast & days bedrest for: sanofi~synthelabo Congestive Hear falure/ Respitatory ines: Inechour or
Slide 29: Building the future, step by step
Building the future, step by step | Penetration slower than anticipated [Sales growing steadily in Europe & USA from a low base [AIL VTE indications to be available end 2004 with access to 80% of the LMWH market [| Cardiology indications in 2006 | Adjustments in commercial policy accompany increasin
Slide 30: Sleeping disorders, Ambien under-diagnosed and under-treated
——_ Sleeping disorders, AMBIEN under-diagnosed and under-treated H1 Consolidated Sales? {EUR m) | Large untreated population! with +21% sleeping problems who do not take any 519 medication: acca aah = 73% in the US usa = 65% in France us = 64% in Japan || 76% of US untreated population have Ht 2002
Slide 31: Sustained performance
Sustained performance | USA: Ne1 with continued strong sales growth: +24% in Junet = sales performance and high patient satisfaction (78%) = co-pay increased in line with overall market and 3 Tier segments driving growth * excellent spontaneous brand awareness among GPs (99%)? and high brand loyalty
Slide 32: Zolpidem MR: Pharmacodynamic studies
Zolpidem MR Pharmacodynamic studies | Objective = Evaluation of next-day residual effects, 8 hours after administration of zolpidem-MR in healthy volunteers > double-blind, placebo and positive control > 18 adult patients and 24 elderly patients (each volunteer receiving the 3 treatments) | Study de
Slide 33: Zolpidem MR: No residual effect
Zolpidem MR No residual effect In the studies validated by a positive control (flunitrazepam), there was no deleterious effect of zolpidem MR on the following parameters: = Vigilance = Memory = Motor function = Awakening behaviour [In adults receiving 12.5 mg of zolpidem MR (standard developed formu
Slide 34: The gold standard: Today and tomorrow
The gold standard: Today and tomorrow | The hypnotic with the widest experience in the world: = Qbillion treatment nights since launch 140 clinical studies including 80.000 subjects in every population Caucasian, Africans, and Asians patients well established pharmaco-vigilance the only product with
Slide 35: ARB: The reference class in hypertension
hypertension. | Dynamic growth! : = Europe — +23% = USA +32% = Worldwide +28% Jin Europe, ARB is No.2 in HTN with 22.8% MS | Therapeutic guidelines in Europe and in the USA position ARBs as first line and also support fixed dose combinations | High level of promotion and investment sustained 41, MAT
Slide 36: Differentiation starts to pay off
Differentiation starts to pay off | Differentiation with “renal and cardiovascular protection” gives the edge | European sales? 283 EUR m (+26%), achieving No.1 position in France, Greece and Switzerland? | Other countries? 51 EUR m (+55%), J USA: = Increased promotional investment has reinvigorated
Slide 37: Outlook: Continued growth Aprovel
Outlook: Continued growth APROVEL | Objectives = USA: maintain market share in a fast growing class = Europe: outgrow the market, improve rank in class | Active support to combo growth | Life Cycle Management program on track to enlarge market definition encompassing hypertension, diabetes and their
Slide 38: Plavix: One of the most successful brands
One of the most Plavipc successful brands |_ Worldwide sales 3° best launch of the last years (EUR TH) (NCE 1998-2002 ranked hy audited world sales? ) 1,091 (#35%) Viagra |= Consolidated ™ Developed USA 612 (#27%) 482 (#55%) H1 2002 H1 2003 Plavix: 10 ranks higher than for YTD June 2002 Strongest gr
Slide 39: Ambitious life cycle program initiated Plavix
Ambitious life cycle program initiated Plavic trials include more than 80,000 patients | Completed trials = CAPRIE, CURE, CLASSIC, CREDO | 2003-2005: = MATCH » Secondary prevention after strake or transient ischemic attack in high risk patients — Clopidogrel + aspirin versus clopidogrel — (7,600 pat
Slide 40: Life Cycle Management Plavix
Life Cycle Management Plavix SCHARIS! | Clopidogrel for High Atherothrombotic Risk = MIA and Ischemic Stabilization, Management and Avoidance = n= 15,200 Clopidogrel ---4 75 mg once daily (n=7,600) Patients aged > 45 years at high-risk of atherothrombotic events * Placebo {| _} |__|. | 4 tab once da
Slide 41: Plavix Growth Avenues
Growth Avenues | Duration of Treatment (DOT): satisfactory progress but significant remaining potential | Increase penetration in all indications = Plavix® still under-represented in certain indications in many countries | Geographic expansion = Reimbursement obtained in Italy and Portugal = Japan:
Slide 42: Among the best growth companies
Among the best {High growth Pharma companies growth companies are becoming a select breed in the Top 20 2004 | J YTD June 2003 i] 1 Johnson & Johnson 1_Amgen 1_Amgen 2 Wyeth 2 Johnson & Johnsan 2 Novartis 3 EISAL 3 Novartis 4 4 SanoftSynthélabo 13:24 4_EISAl 5 5 Aventis 5 Johnson & Johnson 6 6 _ Boe
Slide 43: Finance
Finance synthelabo
Slide 44: Consolidated Sales growth superior to the market
Consolidated Sales growth* superior to the market | Growth on a comparable basi +14.4% Consolidated Sales | Impact of changes in group structure: -0.5% InarIMNbaeureS. | Currency impact: -78% +6.1% = of which +165% (14.455) ~ US Dollar: =3.8% (414.8%") + Japanese Yen: 0.4% > Latin American currencie
Slide 45: High gross margin maintained
in million euros H1 2001 H1 2002 H1 2003 Progression of 1.1 percentage point in Gross Margin at 2002 exchange rates High Gross margin mai | Positive driver = Product mix and productivity improvement | Negative driver = Exchange rate impact on US royalties on Plavix® and Avapro® | At 2002 exchange ra
Slide 46: Improvement of percentage points in operating margin
Improvement of 2 percentage points in operating margin Gnertng Bron | R&D Expenses: + 5.8% (+ 12.9% at 2002 exchange rates) = 15.9% of sales = Phase Ill clinical trials + Life Cycle Management. | SG&A: - 2.8% (+ 5.1% at 2002 exchange rates) = 30.8% of sales = Marketing expenses : +6.6% (at 2002 exch
Slide 47: A balanced geographic spread of operating profit
A balanced geographic spread of operating profit Geographic spread of operating profit” in H1 2003 USA 857 million euros + 6.2% USA: At 2002 exchange rates, 42% operating profit: + 31.2% relative weighting: 46% Other Countries 274 nN euros + 8.3% 13% Europe 922 million euros + 12.9% 45% sanofi~synth
Slide 48: Improvement in net margin
in net margin in million euros, +144 % +28.8 % H1 2002 | At 2002 exchange rates, H1 2003 net profit’: +27.5% H1 2003 * before exceptional items and goodwill amortization Improvement of 1.8 percentage point | Financial Income: 63 Eur m (vs. 28 Eur m H1 2002) Positive factors = Mark ta market adjustme
Slide 49: EPS growth superior to our guidance
EPS* growth superior to our guidance: + 18.6% | EPS": 1.34 euro + 18.6% (at 2002 exchange rates +31.9%) | Guidance: » Anincrease in EPS close to 20% before exceptional iterns and goodwill amortization at an exchange rate of one euro per dollar > The sensitivity of this growth being: 1% for 3 cents |
Slide 50: Cash flow statement and share buy back programs
share buy back programs | Operating Cash flow = 4114 Eur m (vs. 1,087 Eurm in H1 2002) | Change in working capital = -355 Eur m (vs. -697 Eurm) | Capital expenditure = 187 Eur m (vs, 1026 Eur m in H1 2002) ~ Acquisition of §1% of Lorex in April 2002 | Share Buy Back Programs’ in H1 2003: 688 Eur m A
Slide 51: Share Capital
Share Capital Share Capital As of June 30th, 2003 Total 24.8% Public 490% | \voréa 19.5% Employees Treasury 11% Shares 6.0% Total Loreal 27.9% e Employees 1.5% sanofi~synthelabo Becanse Beale aters
Slide 52: Consolidated Profit & Loss Account
Consolidated Profit & Loss Account ns euros H1 2002 H1 2003 Var. | Eurom %CA |Eurom %CA NET SALES 3680 100% | 3,903 100% | 6.1%" Castof goods sald (708) 19.2% | (750) 19.2% | +8.2% GROSS PROFIT 2,974 808% | 3,153 80.8% | +6.0% R&D expenses (687) 16.0% | (621) 15.9% | +58% Selling and general expense
Slide 53: Consolidated Profit & Loss Account (ctd)
Consolidated Profit & Loss Account (ctd) H1 2002 H1 2003 Var. Eurom % CA | Eurom % CA | PROFIT BEFORE TAX AND EXCEPTIONAL ITEMS 1206 328% | 1,388 35.6% | +15.1% Exceptional items 6 1 Income taxes (313) (458) +46.3% Share in protits of equity associates 18 19 45.6% Goodwill amortization (4) 4) Minori
Slide 54: Simplified consolidated statement of cash flows
Simplified consolidated statement of cash flows if ae H1 2002 | H4 2003 | Operating cash flaw 1,087 1114 Change in working capital (697) (385) CASH FLOW PROVIDED BY OPERATING ACTIVITIES 390 759 Capital expenditure (1,028) (187) Proceeds fram disposals 17 6 CASHFLOW USED IN INVESTING ACTIVITIES (1,00
Slide 55: Simplified consolidated balance sheet
Simplified consolidated balance sheet ion euros saiso2| anna] sorsioa| sniina| LIABILITIES AND ASSETS SHAREHOLDERS’ EQUITY Fixed assets 2819 Shareholders’ equity 5905 | 8591 Defered taxes an Minority interests 10 18 Inventories 322 3273 Other long-term liabilities B13 780 receivables and others Cash
Slide 56: Research & Development
Research & Development sanofi~synthelabo Because health mat
Slide 57: A well balanced portfolio of compounds under development
A well balanced portfolio 155 compounds under development Phase | Phase | Phase | Phase 1 Va 1» m Total Cardiovascular / Thrombosis: 3 0 1 2 9 Central Nervous System 5 4 5 4 21 oncology 2 2 1 1 9 Internal Medicine 4 2 1 2 16 Total 19 14 5 8 55 122 compounds in phases II and Ill 133 compounds in prec
Slide 58: R&D Portfolio: Foundation for future growth
R&D Porfolio: Foundation for future growth SSR 128229 SSR 149744 ‘SR 121463 ieeperiem: Aprovel” ‘SSR 182289 ‘SL65.0472 - Pr entra sar iene | So taorr Stascane | SR S86 0 ssp 482073 | Soh aerate ciredutane | 22!Pidem MR ssn 225 : jae ssn or S8R120768 | ssn anion Ssntsowe | SSeiases | sams | cama | Am
Slide 59: R&D Portfolio: Two new products enter phase III
R&D Portfolio: Two new products enter phase Ill {Development stopped for = SR 48692 in the indication IBS’ | Four new compounds entered preclinical development = SSR 97225, antimitotic agent (oncology) = SSR 128129, FGF (fibroblast growth factor) receptor antagonist (oncology) = SSR 162369, dipeptid
Slide 60: Cardiovascular / Thrombosis
Cardiovascular / Thrombosis 60 Approved fondaparinux irbesartan Launched/Lem (oreventon of hromto-emboto everts (dabeto nepropahy, CHF) ater rr ontoped surgery; long tm preverton of VTE hip fracture patents) clopidegrel (unstable angina prevention in tris teres prevenion of athrorbesc ‘evant afer My
Slide 61: Dronedarone: ANDROMEDA, morbidity/mortality study
Dronedarone: ANDROMEDA, morbidity/mortality study { dronedarone 800 mg vs. placebo in high risk patients As of January 10 2003: survival comparison with DIAMOND-CHF = Severely sick population with congestive heart failure and ejection fraction < 35% ity of survival = Global mortality rate under blin
Slide 62: Dronedarone: ANDROMEDA study discontinuation (1)
Dronedarone: ANDROMEDA study discontinuation (1) 1 On January 16 2003, after 627 patients had been enrolled (mean follow-up of 70.4 + 43.9 days), the decision to stop patients’ treatment was taken by the Steering Committee, following the Data Safety Monitoring Board’s recommendation, based on a pote
Slide 63: Dronedarone: ANDROMEDA study discontinuation (2)
Dronedarone: ANDROMEDA study discontinuation (2) | A careful analysis of available data was conducted: = No Torsade de Pointe induced by dronedarone = Analysis of baseline characteristics, concomitant medications (mean of 10 per patient) did not provide an explanation for the excess mortality = Glob
Slide 64: Dronedarone: ANDROMEDA study discontinuation (3)
Dronedarone: ANDROMEDA study discontinuation (3) specific category up to January 16" 2003 Placebo (N=305) Any event 107 (35.1%) Cardiac events Cardiac arrest events 6 (2.0%) Cardiac failure events 35 (11.5%) Arrhythmia events 10 (3.3%) Ventricular arhythmia 5 (1.6%) Supra-ventricular arrhythmia 2 (0
Slide 65: Dronedarone: Phase III programme is proceeding ahead
Dronedarone: Phase Ill programme is proceeding ahead | No safety concern in the two main pivotal atrial fibrillation studies: = EURIDIS + ADONIS (n = 1,200) | Last Data Safety Monitoring Board meeting on 19t May 2003 = OK for completion of the two studies. sanofi~synthelabo Becanse Beale aters
Slide 66: Dronedarone: Phase II study in ICD population
Dronedarone: Phase Il study in ICD* population | CHF patients: LVEF < 40%, implanted with an ICD = 1-month treatment with either dronedarone 600 mg bid or 800 mg bid or 1,000 mg bid or placebo = Number of patients with appropriate ICD intervention — all randomized patients during treatment period 35
Slide 67: Idraparinux: Phase III program
Idraparinux: Phase Ill program Recruitment ongoing for the four efficacy studies: | Van Gogh program in the treatment of VTE and PE = Van Gogh DVT — idraparinux versus vitamin K antagonist - 2,200 patients = Van Gogh PE - idraparinux versus vitamin K antagonist — 2,200 patients = Van Gogh Extension
Slide 68: Idraparinux: A unique profile in a large unsatisfied market
Idraparinux: A unique profile in a large unsatisfied market 11.5 billion treatment days Route of Administration Oral Subcutaneous Posology Once or Twice-a-Day Once-aWeek | YES (INR, ..) Need for Momtering Low therapeutic margin resulting NO in bleeding risks and/or poor compliance Drug, food interac
Slide 69: Oncology
Oncology Approved! Launched / LOM ELOXATIN® oxaliplatin (colorectal canoes) FASTURTECELITEK®| rasburicase (chemotherapy: associated yeperutcemia) (adiwant treatment) tirapazamine sR 258076 (oonemal eal ung cancer, head neck cancel) SR31747 periphericsigma ligand (prostate / breast cancer) SR48882 uv
Slide 70: Tirapazamine: Head & neck cancer TROG study
Tirapazamine: Head & neck cancer 1 TROG study = 122 patients (121 patients, ITT analysis) | Two chemoradiation strategies = One based on tumor hypoxia (tirapazamine) The other based on « chemoboost » (5 FU — control arm) ity Stage III or IV SCC oral cavity, oropharynx, hypopharynx or larynx No evide
Slide 71: Tirapazamine: Preliminary results
Tirapazamine: Head & neck cancer 1 TROG study: Preliminary results ime to locoregional failure 100 3 & i F 80 2 z & 60 3 2 40 8 = Cist TPZ 3 = CstsFU wo <- 20 ne veaeet s ecard ati 95% % i 2 3 4 Years from randomisation sanofi~synthelabo Becanse Beale aters
Slide 72: Central Nervous System
Central Nervous System stunox sameiew’ (| MYSLEE: ipldem som) pase ouanrey) ssRsoa724 Seer ioe ‘eenecpurasy fees sbnaniety ten oy ete a) eepessbaaniey) onset coil mia zelpiderm MR frome fmangenrany, | "pntecmnes mon SR S7667 Sa. osanetant saredutant Gassasamit |g ane swurtopasagint | $a84agourt | sr
Slide 73: SR 58611: Phase III studies in depression
SR 58611: Phase Ill studies in depression [ Target population = Patients with a recurrent MDE of moderate to severe intensity (OSMIV) [Design SR58611A 350 mg bid. N=300 Placebo Eee = Run-In (3-6 days) Paroxetine 20 mg o.d. ontionat Main double-btind phase double bind —— ee —— AR cstcrsion phaie’ > Y
Slide 74: Xaliproden: A causal approach in Alzheimer's disease
Xaliproden: A causal approach in Alzheimer’s disease xaliproden aneurotrophic-like compound hs | Ce CHOLINERGIC NEURONS Increases — Increases neuronal survival Reduces apoptosis Degeneration of forebrain Induces neurite outgrowth cholinergic neurons Reduction in synaptic Improves nee repair connecti
Slide 75: Xaliproden: Phase III studies in Alzheimer's disease
Xaliproden: Phase III studies in Alzheimer’s disease { Design of two identical Phase Ill studies Placebo po* A total of 2,400 patients Double-blind with Alzheimer's xaliproden po* disease 0.5 mgid 18 months « > Primary Efficacy Outcomes (18 months) Secondary outcomes Cognitive function and global de
Slide 76: SR 57667: A causal approach in Alzheimer's and Parkinson's
SR 57667: A causal approach both in Alzheimer’s and Parkinson’s diseases SR 57667 FOREBRAIN CHOLINERGIC SYSTEM MIDBRAIN DOPAMINERGIC SYSTEM In-vitro Increases survival and differentiation © Increases survival and differentiation of of chofinergic neurons dopamineruic 1S Reduces apoptosis and improve
Slide 77: SR 57667: Phase II study in Alzheimer's disease
SR 57667: Phase Il study in Alzheimer’s disease {Design of the study (ALTIMMA) Placebo po* 500 patients with Alzheimer’s disease Double-blind SR 57667B* a 12 months Primary Efficacy Outcomes (12 months) Secondary outcomes Cognitive function and global decline = Functional decline, behavioral symptom
Slide 78: SR 57667: Phase II study in Parkinson's disease
SR 57667: Phase Il study in Parkinson’s disease | One study to assess the effect of SR 57667 (4 mg/day). in patients with early Parkinson’s disease 520 patients Double-blind, placebo-controlled Treatment duration: up to 24 months Primary outcome: time to progression of disability warranting dopamine
Slide 79: SL 65.0155: A dual promnesic and neuroprotective profile
SL 65.0155: A dual promnesic and neuroprotective profile for Alzheimer’s disease 1 SL 65.0155, a neurotrophic and neuroprotective compound, Increases NGF expression in-vitro Improves neuronal repair in-vivo = After lesion of cholinergic septohippocampal pathway, SL 65.0155 maintains synaptic connect
Slide 80: SL 65.0155: Design of phase II study
SL 65.0155: Design of phase II study in Alzheimer’s disease Placebo po 400 patients =SS= 0.5 mgid po with Double-blind mild-to-moderate 2.0 mgid po Alzheimer’s disease 8.0 mgid po 12 weeks ~ - Primary Efficacy Outcomes (12 weeks) Secondary outcomes Cognitive function and global decline = Functional
Slide 81: Internal Medicine
Slide 82: Rimonabant: Phase III program
Slide 83: Obesity/smoking: Priorities of public health
Slide 84: Obesity and Diabetes - a fast aggravating problem
Slide 85: Registration status
Slide 86: Conclusions
Slide 87: H1 2003: On track to reach 2006 objectives
Slide 88: 2003: a remarkable performance despite currency impact
Slide 89: An international presence reinforced by our success in the USA
Slide 90: A promising late stage R&D pipeline
Slide 91: Objective: To become one of the leaders in the Central Nervous System area
Slide 92: A new wave of innovative drugs
Slide 93: Our strategy: Remain in control of our development
Slide 94: ANNEXES
ANNEXES Explanatory notes: All figures in this press release are in French GAAP. In this press release, we refer to our historical sales as “reported” sales. In addition to reported sales, we also present and discuss two other non-GAAP indicators that we believe are useful measurement tools to expla
Slide 95: Sales by therapeutical area
Slide 96: Developed sales H1 2003
Slide 97: Market performance of major products in the USA
Slide 98: SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 5, 2003 SANOFI-SYNTHELABO By: /s/ Marie-Helene Laimay Name: Marie-Helene Laimay Title: